Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lunai Bioworks Inc.RENB · Entity 7981 | Director | June 25, 2024 | June 27, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lunai Bioworks Inc.
Report date June 25, 2024 · Filed June 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase shares of common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.61 · Expires 2034-06-25 | Direct | 46,584 |
Reported balance
After 2024-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-25 · Grant · Acquired 46,584 · Balance 46,584 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2024 Filed Jun 27, 2024 22:53 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | GrantOption to purchase shares of common stock · Derivative | 46,584 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001731122-24-001033 · ownership.xml · derivative · entry 1 McNicol Jayne · CIK 0001866827 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,584 Underlying: Common stock · 46,584 shares Expires 2034-06-25 Read SEC document |
| May 26, 2024 Filed May 31, 2024 01:35 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | GrantOption to Purchase Common Stock · Derivative | 52,817 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001731122-24-000898 · ownership.xml · derivative · entry 1 McNicol Jayne · CIK 0001866827 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,817 Underlying: Common Stock · 52,817 shares Expires 2034-05-26 Read SEC document |
| May 26, 2023 Filed Jun 15, 2023 01:26 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | GrantOption to Purchase Common Stock · Derivative | 79,787 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001731122-23-001136 · ownership.xml · derivative · entry 1 McNicol Jayne · CIK 0001866827 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,787 Underlying: Common Stock · 79,787 shares Expires 2033-05-26 Read SEC document |
| May 26, 2022 Filed Jun 13, 2022 16:56 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | GrantOption to purchase shares of common stock · Derivative | 16,892 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001731122-22-001059 · ownership.xml · derivative · entry 1 McNicol Jayne · CIK 0001866827 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,892 Underlying: Common stock · 16,892 shares Expires 2032-05-26 Read SEC document |
| June 24, 2021 Filed Jun 25, 2021 15:49 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | GrantOption to purchase shares of common stock · Derivative | 26,498 | $0.00 Strike: $5.78 | $0.00 |
DisclosureSEC source: 0001731122-21-001096 · ownership.xml · derivative · entry 1 McNicol Jayne · CIK 0001866827 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,498 Underlying: Common stock · 26,498 shares Expires 2031-06-24 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.